BridgeBio Pharma/BBIO

$26.83

-6.55%
-
1D1W1MYTD1YMAX

About BridgeBio Pharma

BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.

Ticker

BBIO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Neil Kumar

Employees

550

Headquarters

Palo alto, United States

BridgeBio Pharma Metrics

BasicAdvanced
$4.93B
Market cap
-
P/E ratio
-$3.95
EPS
1.06
Beta
-
Dividend rate
$4.93B
1.05603
$44.32
$12.75
1.71M
3.32
-13.34%
-111.72%
-148.01%
529.804
-88.02%
-21.03%
4.09%

What the Analysts think about BridgeBio Pharma

Analyst Ratings

Majority rating from 14 analysts.
Buy

Price Targets

Average projection from 13 analysts.
82.63% upside
High $70.00
Low $33.00
$26.83
Current price
$49.00
Average price target

BridgeBio Pharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-9,888.23% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$1.7M
-57.5%
Net income
$-168.1M
-4.97%
Profit margin
-9,888.23%
123.59%

BridgeBio Pharma Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 5.44%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.92
-$0.98
-$1.08
-$0.96
-
Expected
-$0.83
-$0.83
-$0.82
-$0.91
-$0.92
Surprise
10.7%
17.6%
32.42%
5.44%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for BridgeBio Pharma stock?

BridgeBio Pharma (BBIO) has a market cap of $4.93B as of April 15, 2024.

What is the P/E ratio for BridgeBio Pharma stock?

The price to earnings (P/E) ratio for BridgeBio Pharma (BBIO) stock is 0 as of April 15, 2024.

Does BridgeBio Pharma stock pay dividends?

No, BridgeBio Pharma (BBIO) stock does not pay dividends to its shareholders as of April 15, 2024.

When is the next BridgeBio Pharma dividend payment date?

BridgeBio Pharma (BBIO) stock does not pay dividends to its shareholders.

What is the beta indicator for BridgeBio Pharma?

BridgeBio Pharma (BBIO) has a beta rating of 1.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the BridgeBio Pharma stock price target?

The target price for BridgeBio Pharma (BBIO) stock is $49, which is 82.63% above the current price of $26.83. This is an average based on projections from 13 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell BridgeBio Pharma stock

Buy or sell BridgeBio Pharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing